New Risk • Mar 16
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$138.1m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$26m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$13m net loss in 2 years). Market cap is less than US$100m (AU$138.1m market cap, or US$97.3m). Major Estimate Revision • Mar 02
Consensus EPS estimates fall by 110%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$35.8m to AU$36.9m. Forecast EPS reduced from -AU$0.108 to -AU$0.226 per share. Chemicals industry in Australia expected to see average net income growth of 54% next year. Consensus price target up from AU$1.93 to AU$2.05. Share price rose 4.0% to AU$1.05 over the past week. Reported Earnings • Feb 26
First half 2026 earnings released: AU$0.20 loss per share (vs AU$0.065 loss in 1H 2025) First half 2026 results: AU$0.20 loss per share (further deteriorated from AU$0.065 loss in 1H 2025). Revenue: AU$16.3m (up 21% from 1H 2025). Net loss: AU$42.4m (loss widened 250% from 1H 2025). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Feb 05
Calix Limited to Report First Half, 2026 Results on Feb 24, 2026 Calix Limited announced that they will report first half, 2026 results on Feb 24, 2026 Major Estimate Revision • Dec 20
Consensus revenue estimates increase by 13%, EPS downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$31.7m to AU$35.8m. EPS estimate fell from -AU$0.106 to -AU$0.122 per share. Chemicals industry in Australia expected to see average net income growth of 35% next year. Consensus price target up from AU$1.83 to AU$1.93. Share price rose 28% to AU$0.66 over the past week. New Risk • Dec 19
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$19m Forecast net loss in 3 years: AU$19m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$40m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$19m net loss in 3 years). Market cap is less than US$100m (AU$142.3m market cap, or US$94.0m). Breakeven Date Change • Dec 19
No longer forecast to breakeven The 2 analysts covering Calix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$3.61m in 2028. New consensus forecast suggests the company will make a loss of AU$19.2m in 2028. Tillkännagivande • Sep 22
Calix Limited, Annual General Meeting, Nov 18, 2025 Calix Limited, Annual General Meeting, Nov 18, 2025. Location: hybrid meeting, Australia Breakeven Date Change • Aug 27
Forecast to breakeven in 2028 The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$3.60m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule. Reported Earnings • Aug 26
Full year 2025 earnings released: AU$0.096 loss per share (vs AU$0.14 loss in FY 2024) Full year 2025 results: AU$0.096 loss per share (improved from AU$0.14 loss in FY 2024). Revenue: AU$28.2m (up 17% from FY 2024). Net loss: AU$19.2m (loss narrowed 24% from FY 2024). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 7.5% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Jul 29
Calix Limited to Report Fiscal Year 2025 Results on Aug 26, 2025 Calix Limited announced that they will report fiscal year 2025 results on Aug 26, 2025 New Risk • Jul 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$22m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (AU$144.9m market cap, or US$95.8m). Price Target Changed • May 29
Price target decreased by 14% to AU$1.70 Down from AU$1.98, the current price target is provided by 1 analyst. New target price is 400% above last closing price of AU$0.34. Stock is down 76% over the past year. The company is forecast to post a net loss per share of AU$0.13 next year compared to a net loss per share of AU$0.14 last year. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$15m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (AU$55.8m market cap, or US$33.7m). New Risk • Jan 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$15m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$141.9m market cap, or US$89.3m). Price Target Changed • Jan 22
Price target decreased by 18% to AU$1.63 Down from AU$1.98, the current price target is an average from 3 analysts. New target price is 127% above last closing price of AU$0.72. Stock is down 69% over the past year. The company is forecast to post a net loss per share of AU$0.14 next year compared to a net loss per share of AU$0.14 last year. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$15m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$143.9m market cap, or US$92.7m). New Risk • Nov 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$148.5m (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Market cap is less than US$100m (AU$148.5m market cap, or US$98.3m). Tillkännagivande • Sep 24
Calix Limited, Annual General Meeting, Nov 22, 2024 Calix Limited, Annual General Meeting, Nov 22, 2024. New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$6.1m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Major Estimate Revision • Sep 02
Consensus revenue estimates fall by 23% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from AU$40.0m to AU$30.8m. Forecast losses increased from -AU$0.09 to -AU$0.147 per share. Chemicals industry in Australia expected to see average net income growth of 34% next year. Consensus price target down from AU$3.45 to AU$2.43. Share price rose 4.7% to AU$0.90 over the past week. Reported Earnings • Aug 28
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: AU$0.14 loss per share (further deteriorated from AU$0.13 loss in FY 2023). Revenue: AU$24.2m (up 30% from FY 2023). Net loss: AU$25.3m (loss widened 9.0% from FY 2023). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 83%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Aug 20
Calix Limited to Report Fiscal Year 2024 Results on Aug 27, 2024 Calix Limited announced that they will report fiscal year 2024 results on Aug 27, 2024 New Risk • Aug 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$150.7m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years). Market cap is less than US$100m (AU$150.7m market cap, or US$97.3m). New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Recent Insider Transactions • Mar 14
Non Executive Independent Director recently bought AU$87k worth of stock On the 12th of March, Catriona Deans bought around 50k shares on-market at roughly AU$1.73 per share. This transaction increased Catriona's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. New Risk • Mar 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$41m free cash flow). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$14m net loss in 2 years). Major Estimate Revision • Feb 29
Consensus estimates of losses per share improve by 26% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from AU$25.7m to AU$27.5m. EPS estimate increased from -AU$0.107 per share to -AU$0.079 per share. Chemicals industry in Australia expected to see average net income growth of 22% next year. Consensus price target down from AU$6.27 to AU$5.77. Share price fell 6.2% to AU$1.91 over the past week. Reported Earnings • Feb 25
First half 2024 earnings released: AU$0.07 loss per share (vs AU$0.055 loss in 1H 2023) First half 2024 results: AU$0.07 loss per share (further deteriorated from AU$0.055 loss in 1H 2023). Revenue: AU$12.2m (up 41% from 1H 2023). Net loss: AU$12.6m (loss widened 37% from 1H 2023). Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 16
Calix Limited to Report First Half, 2024 Results on Feb 23, 2024 Calix Limited announced that they will report first half, 2024 results on Feb 23, 2024 Tillkännagivande • Dec 19
Calix Limited Announces New Board Appointments, Effective 1 January 2024 Calix Limited announced the appointments of Dr Sarah Ryan and Peter Dixon to the Calix board of directors as non-executive directors. Dr Ryan and Mr. Dixon's appointments will be effective from 1 January 2024. At the Calix 2022 Annual General Meeting, Calix Chair, Peter Turnbull noted the board's proactive approach to board succession and renewal to ensure the composition of the board is appropriate at all times to support the delivery of Calix's strategic goals. This process has been underway for some time and these latest appointments represent a major next step in Calix's board renewal. A further step is the expected retirement of Peter Turnbull prior to 30 June 2024, with Alison Deans set to become the new chair following Peter Turnbull's retirement. These changes will result in the Calix Board being comprised of four highly experienced non-executives and two executive directors, further enhancing the governance of the company. As a non-executive director and former senior operational executive, Dr Ryan brings extensive global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a particular emphasis on innovation and technology enabled solutions, Dr Ryan has led and helped to build organizations across the energy, natural resources, and infrastructure sectors. Dr Ryan is currently a non-executive director of Viva Energy Group Limited (ASX:VEA), Aurizon Holdings Limited (ASX:AZJ), Transurban Group (ASX:TCL) and the Future Battery Industries Co- operative Research Centre. Until recently, Dr Ryan was a non-executive director of Oz Minerals Limited (ASX:OZL) and Woodside Energy Group Limited (ASX:WDS). Dr Ryan is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.Dr Ryan holds a Bachelor of Science in Geology from the University of Melbourne, a Bachelor of Science (First Class Honours) in Geophysics from the University of Adelaide, and a PhD in Petroleum Geology and Geophysics from the University of Adelaide. Dr Ryan is also a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE), a Fellow of the Australian Institute of Energy, a Member of the Australian Institute of Company Directors, a Member of Women Corporate Directors, and a member of Chief Executive Women. With over 25 years of deep and diverse experience across the legal, investment banking and funds management sectors, Mr. Dixon brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Mr. Dixon is currently Chief Strategy Officer for HPX Group (which provides legal, compliance, governance and workplace services to a diverse range of clients across Australia and New Zealand), and is a non-executive director at Johns Lyng Group Limited. Mr. Dixon's investment banking and legal experience includes private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience at MA Financial Group initially as an investment banker and ultimately as the group's General Counsel. Mr. Dixon also spent time earlier in his career at Macquarie Group Limited (ASX:MQG) in various roles across corporate strategy, investment management and corporate advisory. Peter's unique combination of skills and experience including in relation to complex corporate transactions and strategic options and execution will directly support Calix's strategic goals. Mr. Dixon holds a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales. Mr. Dixon has previously been admitted to practice as a solicitor in New South Wales and in England and Wales. Price Target Changed • Oct 25
Price target decreased by 11% to AU$7.33 Down from AU$8.27, the current price target is an average from 3 analysts. New target price is 156% above last closing price of AU$2.86. Stock is down 50% over the past year. The company is forecast to post a net loss per share of AU$0.11 next year compared to a net loss per share of AU$0.13 last year. Tillkännagivande • Oct 17
Calix Limited, Annual General Meeting, Nov 16, 2023 Calix Limited, Annual General Meeting, Nov 16, 2023, at 09:00 AUS Eastern Standard Time. Agenda: To consider remuneration report; to consider re election of Helen Fisher; to consider election of Alison Deans; to consider appointment of auditor; and to consider other matters. Major Estimate Revision • Aug 30
Consensus EPS estimates fall by 29% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from AU$28.8m to AU$26.8m. Losses expected to increase from AU$0.083 per share to AU$0.11. Chemicals industry in Australia expected to see average net income decline 11% next year. Consensus price target down from AU$8.50 to AU$8.27. Share price fell 12% to AU$4.00 over the past week. Reported Earnings • Aug 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: AU$0.14 loss per share (further deteriorated from AU$0.10 loss in FY 2022). Revenue: AU$18.6m (flat on FY 2022). Net loss: AU$23.2m (loss widened 42% from FY 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 55%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 70% per year, which means it is well ahead of earnings. Tillkännagivande • Aug 21
Calix Limited to Report Fiscal Year 2023 Results on Aug 24, 2023 Calix Limited announced that they will report fiscal year 2023 results on Aug 24, 2023 Major Estimate Revision • Feb 27
Consensus revenue estimates decrease by 10%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from AU$25.4m to AU$22.8m. EPS estimate increased from -AU$0.085 to -AU$0.073 per share. Chemicals industry in Australia expected to see average net income growth of 23% next year. Consensus price target of AU$8.50 unchanged from last update. Share price rose 5.1% to AU$5.52 over the past week. Reported Earnings • Feb 21
First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.047 loss in 1H 2022) First half 2023 results: AU$0.055 loss per share (further deteriorated from AU$0.047 loss in 1H 2022). Revenue: AU$8.63m (down 12% from 1H 2022). Net loss: AU$9.17m (loss widened 23% from 1H 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 87% per year, which means it is well ahead of earnings. Tillkännagivande • Feb 13
Calix Limited to Report First Half, 2023 Results on Feb 21, 2023 Calix Limited announced that they will report first half, 2023 results on Feb 21, 2023 Tillkännagivande • Jan 30
Calix Limited Receives Funding from the Australian Renewable Energy Agency and from Germany's Federal Ministry of Education and Research Calix Limited announced that the Solar Methanol Project (the Project), of which it is a consortium member, has been awarded funding to develop the production of sustainable fuels from captured process CO2 emissions. As announced by the Hon Chris Bowen MP, Minister for Climate Change and Energy on 27 January, the "HyGATE" Solar Methanol Project has been awarded AUD 19.48 million from the Australian Renewable Energy Agency (ARENA) and 13.2 million (AUD 20.19 million) from Germany's Federal Ministry of Education and Research (BMBF) to develop a world-first green methanol demonstration plant in Port Augusta, South Australia. The Solar Methanol Project Exporting green hydrogen produced in Australia to Germany offers the promise of leveraging Australia's abundant renewable energy resources to help the decarbonisation of German industry. Methanol is a versatile hydrogen derivative and has the potential to act as an effective green hydrogen carrier. Its clean and economical synthesis could help enable the decarbonisation of hard-to-abate transport sectors such as aviation and shipping. In addition to Calix, the Solar Methanol Project consortium includes Australian cleantech company Vast Solar and leading engineering and consultancy firm Fichtner, and is supported by the Australian Solar Thermal Institute. The Project aims to integrate several innovative low emission technologies to source renewable power and process heat, green hydrogen electrolysis, and, with Calix's Leilac technology, renewably powered electric calcination of limestone and the efficient capture of unavoidable process CO2 emissions. The Project intends to renewably power a 10MW electrolyser to produce green hydrogen, and a lime plant that produces CO2 as an unavoidable process emission. The clean energy, hydrogen and CO 2 will then be used to synthesise up to 7,500 tonnes per year of green methanol to be developed for use as a sustainable transport fuel. The Project aims to be a catalyst for a solar methanol industry in Australia, with the potential to significantly scale domestic green fuel use as well as potential exports to Germany and other global markets. Price Target Changed • Nov 16
Price target decreased to AU$8.00 Down from AU$9.25, the current price target is an average from 2 analysts. New target price is 65% above last closing price of AU$4.85. Stock is down 39% over the past year. The company is forecast to post a net loss per share of AU$0.089 next year compared to a net loss per share of AU$0.10 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 08
Australian Renewable Energy Agency Awards Grant to Calix Limited Calix Limited announced it has been awarded a $947,035 grant by the Australian Renewable Energy Agency (ARENA) to help fund a Basis of Design (BOD) and Front-End Engineering and Design (FEED) study for a renewably powered demonstration plant for its Zero Emissions Steel TechnologY (ZESTY). The $947,035 grant from ARENA will provide approximately 48% of the funding for an eleven-month study for a 30,000 tonne per annum ZESTY-iron demonstration plant. The proposed renewably powered ZESTY-iron plant will produce green hydrogen for the direct reduction of iron ore to sponge iron. With no carbon involved throughout the process, the proposed ZESTY reactor will demonstrate a new approach to zero emissions iron and steel. Calix's ZESTY demonstration plant will also be compatible with intermittent operation, enabling economical use of low cost renewable power and will be compatible with load balancing applications for the energy grid. The project will cover both the BOD and the FEED study required to determine the final location, specification and cost of the demonstration plant before a Final Investment Decision is taken. The project will also further establish key partnerships in industry across the hydrogen, iron ore and renewables sectors, in addition to possible end users of green iron through the Heavy Industry Low-carbon Transition Cooperative Research Centre (HILT CRC), facilitating knowledge sharing and the ongoing development of an ecosystem for sustainable heavy industry in Australia. Major Estimate Revision • Oct 29
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 losses of -AU$0.09 per share expected, vs -AU$0.07 per share profit forecast previously. Revenue forecast reaffirmed at AU$23.3m. Chemicals industry in Australia expected to see average net income growth of 19% next year. Consensus price target down from AU$9.25 to AU$8.00. Share price fell 19% to AU$4.44 over the past week. Price Target Changed • Oct 28
Price target decreased to AU$8.00 Down from AU$9.43, the current price target is an average from 2 analysts. New target price is 80% above last closing price of AU$4.44. Stock is down 14% over the past year. The company is forecast to post a net loss per share of AU$0.089 next year compared to a net loss per share of AU$0.10 last year. Tillkännagivande • Oct 21
Calix Limited has completed a Follow-on Equity Offering in the amount of AUD 60.000004 million. Calix Limited has completed a Follow-on Equity Offering in the amount of AUD 60.000004 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,186,814
Price\Range: AUD 4.55
Transaction Features: Subsequent Direct Listing Major Estimate Revision • Aug 30
Consensus revenue estimates fall by 15% The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from AU$27.4m to AU$23.3m. Forecast losses increased from -AU$0.06 to -AU$0.07 per share. Chemicals industry in Australia expected to see average net income growth of 6.3% next year. Consensus price target broadly unchanged at AU$9.25. Share price was steady at AU$6.55 over the past week. Reported Earnings • Aug 24
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: AU$0.10 loss per share (down from AU$0.061 loss in FY 2021). Revenue: AU$18.5m (down 3.9% from FY 2021). Net loss: AU$16.3m (loss widened 79% from FY 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 48%, compared to a 12% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 102% per year, which means it is well ahead of earnings. Tillkännagivande • Aug 19
Calix Limited to Report Fiscal Year 2022 Results on Aug 24, 2022 Calix Limited announced that they will report fiscal year 2022 results on Aug 24, 2022 Price Target Changed • Jun 24
Price target increased to AU$9.43 Up from AU$8.78, the current price target is an average from 2 analysts. New target price is 50% above last closing price of AU$6.29. Stock is up 133% over the past year. The company is forecast to post earnings per share of AU$0.05 next year compared to a net loss per share of AU$0.061 last year. Tillkännagivande • May 17
Pilbara Minerals and Calix Announces $20 Million Australian Government Modern Manufacturing Initiative Grant Awarded Pilbara Minerals and Calix announced the award of a $20 million grant under the Australian Government's Modern Manufacturing Initiative (MMI) - Manufacturing Translation Stream, towards the development of the Mid-Stream Project at the Pilgangoora Project. The MMI grant represents a significant step forward in the progression of the Mid-Stream Project, which will be used as part of a proposed Joint Venture to be entered between the Parties to support the design, procurement, construction, and commissioning of the Mid-Stream Project Demonstration Plant (Demonstration Plant). Following execution of a Memorandum of Understanding (MoU) in May 2021 between Pilbara Minerals and Calix, a scoping study (Scoping Study) has recently been completed by Lycopodium Minerals in conjunction with the Pilbara Minerals and Calix teams. The purpose of the Scoping Study was to assess the technical viability of developing a demonstration scale chemicals facility at the Pilgangoora Project to produce lithium salts from fines flotation spodumene concentrate produced at the Pilgangoora Project, thereby supporting a potential pathway towards future commercial production of "value-added" lithium products at the Pilgangoora Project and globally. The lithium-ion battery supply market is rapidly evolving with large scale development occurring through all segments of the supply chain. Several prominent themes are shaping the industry including product cost (per lithia unit), product quality (purity), carbon energy reduction and waste management (particularly for the European market). The objective of the Mid-Stream Project is to deliver a superior "value-added" lithium raw material that outperforms across the key metrics of product cost, quality, carbon energy reduction and waste reduction/handling. Works undertaken to date have explored alternative solutions to achieve these aims, including reviewing and testing alternate process paths, equipment selection and end-product types. The Scoping Study supported the technical viability of the Mid-Stream Project at a Scoping Study level to deploy an innovative calcination technology owned by Calix which is proposed to be integrated into a chemical concentration process at the Pilgangoora Project to produce a new end product, with the current focus being a lithium phosphate salt as a key "value-added" product for global distribution. Breakeven Date Change • May 02
Forecast to breakeven in 2022 The 2 analysts covering Calix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$8.13m in 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Mar 10
Calix Limited Achieves Regulatory Approval for BOOSTER-Mag Calix Limited announced it has received Australian Pesticides and Veterinary Medicines Authority approval for its safe, environmentally-friendly crop protection product, BOOSTER-Mag. The registration of BOOSTER-Mag is the culmination of six years of scientifically rigorous product and application development and is a major milestone for Calix and its Biotech business. BOOSTER-Mag is the first registration of a magnesium hydroxide insecticide in the world. This initial registration validates that the unique form of Calix materials can be safely applied to suppress a highly destructive crop pest. With suppression efficacy also apparent on additional crop pests and a variety of crop diseases, the initial registration provides a solid basis to expand the addressable market. Major Estimate Revision • Mar 10
Consensus forecasts updated The consensus outlook for 2022 has been updated. Now expected to report loss of -AU$0.04 instead of AU$0.01 per share profit in 2022. Revenue forecast reaffirmed at AU$22.0m. Chemicals industry in Australia expected to see average net income growth of 33% next year. Consensus price target up from AU$6.92 to AU$7.07. Share price rose 4.9% to AU$6.79 over the past week. Major Estimate Revision • Mar 01
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from AU$24.7m to AU$22.0m. EPS estimate unchanged from AU$0.012 per share at last update. Chemicals industry in Australia expected to see average net income growth of 33% next year. Consensus price target of AU$6.92 unchanged from last update. Share price rose 13% to AU$5.75 over the past week. Reported Earnings • Feb 25
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First half 2022 results: AU$0.047 loss per share (down from AU$0.017 loss in 1H 2021). Revenue: AU$9.82m (up 6.6% from 1H 2021). Net loss: AU$7.48m (loss widened 203% from 1H 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) exceeded analyst estimates by 764%. Over the next year, revenue is forecast to grow 34%, compared to a 20% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 89% per year, which means it is well ahead of earnings. Board Change • Feb 24
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Helen Fisher was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 10
Calix Limited to Report First Half, 2022 Results on Feb 23, 2022 Calix Limited announced that they will report first half, 2022 results on Feb 23, 2022 Tillkännagivande • Dec 21
Pilbara Minerals Limited and Calix Limited Reports on Initiatives to Develop Value-Added Lithium Products At Pilbara Minerals' 100% Owned Pilgangoora Project Pilbara Minerals Limited and Calix Limited further reported on initiatives to develop value-added lithium products at Pilbara Minerals' 100% owned Pilgangoora Project. Following execution of a Memorandum of Understanding (MOU) in May 2021 between Pilbara Minerals and Calix, a Scoping Study for a Mid-Stream Product Demonstration Plant ("Scoping Study") commenced, which is nearing completion. The Scoping Study aims to support the development of a Demonstration Plant at the Pilgangoora Project ("Pilgangoora") to produce lithium salts from fines-flotation spodumene concentrate, supporting a pathway towards potential future commercial production of value-added lithium products at Pilgangoora. The Scoping Study (undertaken by Lycopodium Minerals in conjunction with the Pilbara Minerals and Calix teams) is assessing the potential development of a new refining process to produce high purity lithium phosphate precipitate from Calix-calcined fines spodumene concentrate supplied from the Pilgangoora Project. This concentrated lithium salt from the Pilgangoora Project ("Mid-Stream Product"), could support downstream lithium raw material and cathodes demand. Technical work contributing to the Scoping Study (including testwork, process design and engineering) is now complete. Completion of the commercial and economic evaluation contributing to the Scoping Study is expected early in the New Year, following which a final review of the results will be undertaken by the boards of Pilbara Minerals and Calix with results released shortly thereafter. Subject to the results being commercially and technically satisfactory to both Pilbara Minerals and Calix, in accordance with the MOU the parties will then progress negotiations for the formation of a joint venture and agree a work program to develop a Demonstration Plant at the Pilgangoora Project and ultimately seek to commercialise the Mid-Stream Product's process technology in respect of lithium phosphate applications on a worldwide basis. The lithium-ion supply chain is rapidly evolving with large scale development occurring through all segments of the supply chain. Several prominent forces are shaping the industry including product cost (per lithia unit), product quality (purity), carbon energy reduction and waste management (particularly for the European market). Pilbara Minerals Mid-Stream Project objective is to deliver a superior value-added lithia product that exceeds across these metrics of product cost, quality, carbon energy reduction and waste reduction/handling. The project work to date has comprised exploring alternate solutions to achieve these aims, including reviewing and testing alternate process paths, equipment selection and end- product types. The project has now been narrowed down to a preferred process route and end-product. The process route under investigation is unique in the use of both the calcination processing technology and chemical concentration process. Although the project is in its early development phase, the test work and engineering to date which has contributed to the initial Scoping Study provides strong indications that the new mid-stream product (and process path) can be expected to deliver on the desired metrics of an improved value-added lithia product. In particular through a reduction in carbon energy intensity, reduction in shipped volumes (through higher concentration product) and providing a more easily handled product. The metrics of product production cost and quality will however need to be further assessed as the project moves through the subsequent phases of study and further development. Australian spodumene is a raw material feed to a high-value chemical industry that is largely conducted outside of Australia. Producing a high lithium-content intermediate salt product on site at Pilgangoora, will result in a portion of the value traditionally retained by downstream spodumene converters outside of Australia being retained in-country. The value-added Mid-Stream product is also expected to be able to access diverse markets worldwide. Pilbara Minerals together with Lycopodium Minerals embarked on a testwork programme to develop a flowsheet to produce a lithium phosphate salt. The testwork programme was initiated by using a produced synthetic lithium sulphate leach solution to produce small quantities of lithium phosphate precipitate. Subsequent testwork phases further developed the flowsheet to produce high purity lithium phosphate precipitates from Calix-calcined Pilgangoora spodumene concentrate. Following laboratory scale testwork, lithium phosphate has been selected as the preferred product, having demonstrated superior performance to other alternatives evaluated to date. Other forms of lithium salts will continue to be considered for potential process optimization in future study works. Flowsheet test work to-date has demonstrated >90% overall lithium recovery to final high purity lithium phosphate product. Pilbara Minerals' mid-stream project development is expected to be progressed utilizing unallocated spodumene concentrate production capacity available from the Pilgangoora Project over time, without disrupting existing customer offtake arrangements, including the POSCO and Pilbara Minerals downstream joint venture. Reported Earnings • Aug 25
Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.05 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$19.2m (up 37% from FY 2020). Net loss: AU$9.11m (loss widened 29% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 57% per year, which means it is well ahead of earnings. Price Target Changed • Jul 12
Price target increased to AU$3.48 Up from AU$2.96, the current price target is an average from 3 analysts. New target price is 7.4% above last closing price of AU$3.24. Stock is up 290% over the past year. Major Estimate Revision • Apr 08
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 losses of -AU$0.007 per share expected, vs -AU$0.00058 per share profit forecast previously. Revenue forecast reaffirmed at AU$19.9m. Chemicals industry in Australia expected to see average net income growth of 39% next year. Consensus price target of AU$2.85 unchanged from last update. Share price fell 2.6% to AU$2.22 over the past week. Major Estimate Revision • Mar 02
Analysts update estimates Analysts forecast the company to report a profit instead of a loss in 2021, raising their consensus EPS forecasts from -AU$0.0038 to AU$0.014. No change was made to the revenue estimate which at the last update was AU$20.4m. The Chemicals industry in Australia is expected to see an average net income growth of 37% next year. The consensus price target increased from AU$1.40 to AU$1.67. Share price is up 13% to AU$2.15 over the past week. 
